Akebia Therapeutics, Inc. (AKBA) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -21.21M | 31.13M | 28.11M | 22.34M | -13.59M | -4.47M | -6.7M | -10.07M | -19.43M | -2.31M | -7.17M | 3.63M |
| Operating CF Margin % | -39.61% | 54.02% | 47.83% | 35.77% | -23.7% | -9.6% | -17.89% | -23.06% | -59.59% | -4.11% | -17.05% | 6.44% |
| Operating CF Growth % | -56.08% | 797.02% | 519.79% | 321.98% | 30.08% | -93.5% | 6.59% | -377.38% | -10.8% | 95.78% | -121.2% | 111.84% |
| Net Income | -9.05M | -12.24M | 540K | 247K | 6.11M | -22.8M | -20.04M | -8.58M | -17.98M | 614K | -14.49M | -11.83M |
| Depreciation & Amortization | 328K | 321K | 318K | 316K | 314K | 13.54M | 9.37M | 9.41M | 9.38M | 9.4M | 9.41M | 9.41M |
| Stock-Based Compensation | 3.67M | 3.2M | 3.22M | 2.68M | 2.19M | 0 | 1.65M | 2.07M | 2.36M | 1.51M | 1.82M | 3.49M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 715K | 277K |
| Other Non-Cash Items | 8.39M | 17.98M | 4.8M | 14.01M | 7.53M | 8.03M | 9.98M | 677K | 1.97M | 2.37M | -418K | -1.23M |
| Working Capital Changes | -24.54M | 21.87M | 19.23M | 5.1M | -29.73M | -3.23M | -7.66M | -13.64M | -15.15M | -16.21M | -4.21M | 3.52M |
| Change in Receivables | -15.7M | 19.1M | 6.16M | -11.53M | -27.87M | -3.07M | -2.4M | -3.15M | 12.67M | -16.7M | -3.02M | -687K |
| Change in Inventory | -2.54M | -17.42M | 6.9M | -7.65M | -4.95M | -8.5M | -545K | -14.93M | -4.43M | -11.78M | -1.59M | 3.48M |
| Change in Payables | -7.79M | 10.42M | -8.83M | 3.73M | -2.23M | 2.39M | -3.03M | 6.78M | -7.5M | 4.5M | 2.31M | -3.04M |
| Cash from Investing | -62K | -7.88M | -77K | -126K | 154K | -2K | -2K | -29K | 0 | 0 | 0 | 0 |
| Capital Expenditures | -62K | -162K | -77K | -126K | -18K | -2K | -2K | -29K | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | 0.12% | 0.28% | 0.13% | 0.2% | 0.03% | 0% | 0.01% | 0.07% | - | - | - | - |
| Acquisitions | 0 | 172K | 0 | 0 | 172K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -7.89M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -926K | -4.85M | 1.11M | 1.72M | 74.94M | 22.32M | 1.22M | 7.64M | 18.48M | -1.29M | 50K | -8M |
| Debt Issued (Net) | -1.08M | -4.91M | 0 | 0 | 9.54M | -1.27M | 0 | 7.63M | 274K | -8M | 0 | -8M |
| Equity Issued (Net) | 151K | 63K | 152K | 1.72M | 64.92M | 22.32M | 1.75M | 14K | 18.06M | 6.71M | 50K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -63K | 0 | 0 | 0 | -750K | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 961K | 0 | 482K | 1.27M | -522K | 0 | 141K | 1K | 0 | 0 |
| Net Change in Cash | -22.2M | 18.4M | 29.14M | 23.93M | 61.51M | 17.85M | -5.47M | -2.46M | -957K | -3.6M | -7.12M | -4.37M |
| Free Cash Flow | -21.21M | 30.97M | 28.03M | 22.22M | -13.61M | -4.47M | -6.7M | -10.1M | -19.43M | -2.31M | -7.17M | 3.63M |
| FCF Margin % | -39.61% | 53.74% | 47.69% | 35.57% | -23.73% | -9.61% | -17.89% | -23.13% | -59.59% | -4.11% | -17.05% | 6.44% |
| FCF Growth % | -55.88% | 793.08% | 518.52% | 320.1% | 29.99% | -93.59% | 6.56% | -378.18% | -10.8% | 95.78% | -121.2% | 111.84% |
| FCF per Share | -0.08 | 0.12 | 0.10 | 0.08 | -0.06 | -0.02 | -0.03 | -0.05 | -0.09 | -0.01 | -0.04 | 0.02 |
| FCF Conversion (FCF/Net Income) | 2.34x | -2.54x | 52.05x | 90.47x | -2.22x | 0.20x | 0.33x | 1.17x | 1.08x | -3.76x | 0.49x | -0.32x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |